Rash and liver dysfunction related to lamotrigine therapy

Journal of Pharmacy Technology

Volumn 24, Issue 1, 2008, Pages 17-21

  Serwetman, Lea R C ^a,b   Krikorian, Susan A ^a,c   Javedan, Houman ^a  

^a MOUNT AUBURN HOSPITAL   (United States)

^b CVS Caremark   (United States)

^c MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA TOCOPHEROL; AMFEBUTAMONE; CALCIUM CARBONATE; CITALOPRAM; DIPHENHYDRAMINE; DOCUSATE SODIUM; HYDROCORTISONE; LAMOTRIGINE; LEVOTHYROXINE; LIVER ENZYME; LOPERAMIDE; LORAZEPAM; MULTIVITAMIN; PARACETAMOL; PENICILLIN G; PSYLLIUM HYDROCOLLOID; QUETIAPINE; SULFANILAMIDE; ZINC SULFATE;

AGED; ARTICLE; BEDTIME DOSAGE; BIPOLAR DISORDER; CASE REPORT; CHILL; CLINICAL FEATURE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HUMAN; LIVER DYSFUNCTION; LIVER FAILURE; MACULOPAPULAR RASH; MORNING DOSAGE; NARANJO PROBABILITY SCALE; NAUSEA; PREDICTION; PROBABILITY; PRURITUS; RASH; RATING SCALE; RISK FACTOR; STEVENS JOHNSON SYNDROME; SYMPTOM;

EID: 38849128843     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250802400105     Document Type: Article

References (17)

1. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: a review of its use in bipolar disorder. Drugs 2003;63:2029-50.
2. Selek S, Savas HA, Savas E, Herken H, Tutkun H, Gergerlioglu HS. Jaundice and hepatic enzyme induction during lamotrigine therapy in a bipolar II patient. Int J Psychiatry Clin Pract 2005;9:65-7.
3. Schlienger RG, Knowles SR, Shear NH. Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology 1998;51: 1172-5.
4. Mylonakis E, Vittorio CC, Hollik DA, Rounds S. Lamotrigine overdose presenting as anticonvulsant hypersensitivity syndrome. Ann Pharmacother 1999;33:557-9. DOI 10.1345/aph.18383
5. Bowden CL, Asnis GM, Ginsberg LD, Bentley B, Leadbetter R, White R. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004;27:173-84.
6. Mecarelli O, Pulitano P, Mingoia M, et al. Acute hepatitis associated with lamotrigine and managed with the molecular adsorbents recirculating system (MARS). Epilepsia 2005;46:1687-9.
7. Mansouri P, Rabiei M, Pourpak Z, Hallaji Z. Toxic epidermal necrolysis associated with concomitant use of lamotrigine and carbamazepine: a case report. Arch Dermatol 2005;141:788-9.
8. Schaub JEM, Williamson PJ, Barnes EW, Trewby PN. Multisystem adverse reaction to lamotrigine (letter). Lancet 1994;344:481.
9. Makin AJ, Fitt S, Williams R. Fulminant hepatic failure induced by lamotrigine (letter). BMJ 1995;311:292.
10. Arnon R, DeVivo D, Defelice AR, Kazlow PG. Acute hepatic failure in a child treated with lamotrigine. Pediatr Neurol 1998;18:251-2.
11. Fayad M, Choueiri R, Mikati M. Potential hepatotoxicity of lamotrigine. Pediatr Neurol 2000;22:49-52.
12. Overstreet K, Costanza C, Behling C, Hassanin T, Masliah E. Fatal progressive hepatic necrosis associated with lamotrigine treatment: a case report and literature review. Dig Dis Sci 2002;47:1921-5.
13. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
14. Hirsch LJ, Weintraub DB, Buchsbaum R, et al. Predictors of lamotrigine-associated rash. Epilepsia 2006;47:318-22.
15. Wong ICK, Mawer GE, Sander J. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999;33:1037-42. DOI 10.1345/aph.18422
16. Besag FMC. Approaches to reducing the incidence of lamotrigine-induced rash. CNS Drugs 2000;13:21-33.
17. Hebert AA, Ralston JP. Cutaneous reactions to anticonvulsant medications. J Clin Psychiatry 2001;62(suppl 14):22-6.